The alkalizer citrate reduces serum uric acid levels and improves renal function in hyperuricemic patients treated with the xanthine oxidase inhibitor allopurinol

Endocrine Research

Volumn 35, Issue 4, 2010, Pages 145-154

  Saito, Jun ^a   Matsuzawa, Yoko ^a   Ito, Hiroko ^a   Omura, Masao ^a   Ito, Yuzuru ^b   Yoshimura, Koichiro ^c   Yajima, Yuki ^d   Kino, Tomoshige ^e   Nishikawa, Tetsuo ^a  

^a YOKOHAMA ROSAI HOSPITAL   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c YOKOSUKA KYOSAI HOSPITAL   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Allopurinol; Citrate preparation; Creatinine clearance; Hyperuricemia; Renal function

Indexed keywords

ALLOPURINOL; CITRIC ACID; URIC ACID;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERURICEMIA; KIDNEY CLEARANCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; URIC ACID BLOOD LEVEL;

ALLOPURINOL; CITRIC ACID; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; URIC ACID; XANTHINE OXIDASE;

EID: 77958460141     PISSN: 07435800     EISSN: 15324206     Source Type: Journal    
DOI: 10.3109/07435800.2010.497178     Document Type: Article

References (41)

1. Costa A, Igualá I, Bedini J, Quintó L, Conget I. Uric acid concentration in subjects at risk of type 2 diabetes mellitus: relationship to components of the metabolic syndrome. Metabolism 2002;51:372-375.
2. Chu NF, Wang DJ, Liou SH, Shieh SM. Relationship between hyperuricemia and other cardiovascular disease risk factors among adult males in Taiwan. Eur J Epidemiol 2000;16:13-17.
3. Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN. Uric acid and the development of metabolic syndrome in women and men. Metabolism 2008;57:845-852.
4. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007;120:442-447.
5. Ebrahimpour P, Fakhrzadeh H, Heshmat R, Bandarian F, Larijani B. Serum uric acid levels and risk of metabolic syndrome in healthy adults. Endocr Pract 2008;14:298-304.
6. Matsuura F, Yamashita S, Nakamura T, Nishida M, Nozaki S, et al. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism 1998;47: 929-933.
7. Tamba S, Nishizawa H, Funahashi T, Okauchi Y, Ogawa T, et al. Relationship between the serum uric acid level, visceral fat accumulation and serum adiponectin concentration in Japanese men. Intern Med 2008;47:1175-1180.
8. Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, et al. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008;19:2407-2413.
9. Domrongkitchaiporn S, Sritara P, Kitiyakara C, Stitchantrakul W, Krittaphol V, et al. Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study. J Am Soc Nephrol 2005;16:791-799.
10. Gibson T, Highton J, Potter C, Simmonds HA. Renal impairment and gout. Ann Rheum Dis 1980;39:417-423.
11. Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep 2009;11:135-140.
12. Emmerson BT. Drug control of gout and hyperuricaemia. Drugs 1978;16:158-166.
13. Elion GB. The purine path to chemotherapy. Science 1989;244:41-47.
14. Elion GB. Enzymatic and metabolic studies with allopurinol. Ann Rheum Dis 1966;25(6 Suppl.):608-614.
15. Hesse A, Tiselius HG, Jahnen A. Uric acid stones. In: Williams HE, ed. Urinary Stones: Diagnosis, Treatment and Prevention of Recurrence. Basel, Switzerland: S. Karger AG; 2002:80-83.
16. Chugtai MN, Khan FA, Kaleem M, Ahmed M. Management of uric acid stone. J Pak Med Assoc 1992;42:153-155.
17. Petritsch PH. Uric acid calculi: results of conservative treatment. Urology 1977;10: 536-538.
18. Nakamura T, Uchida M, Uchino H. Studies on hyperuricemia of gout by means of the uric acid clearance. Uric Acid Res 1977;1:45-61 (in Japanese).
19. Matoushek E, Huber RD. Das Harnsäuresteinleiden. In: Matoushek E, ed. Urolithiasis Pathogenese, Diagnostik, Therapie. Stuttgart: F. K. Schattauer Verlag; 1981:134-136.
20. Robinson MR, Leitao VA, Haleblian GE, Scales CD Jr, Chandrashekar A, et al. Impact of long-term potassium citrate therapy on urinary profiles and recurrent stone formation. J Urol 2009;181:1145-1150.
21. Dumaine RL, Montalescot G, Steg PG, Ohman EM, Eagle K, et al. Renal function, atherothrombosis extent, and outcomes in high-risk patients. Am Heart J 2009;158:141-148.
22. Committee for the Preparation of Guidelines for the Management of Hyperuricemia and Gout, Japanese Society of Gout and Nucleic Acid Metabolism. Guideline for the Management of Hyperuricemia and Gout. Abridged Edition. Tokyo: Japanese Society of Gout and Nucleic Acid Metabolism; 2004:19-21.
23. Bach D, Hesse A, Strenge A, Vahlensieck W. Prevention of urinary calculi by means of a benzbromarone - citrate combination. Fortschr Med 1980;98:1752-1755.
24. Byer K, Khan SR. Citrate provides protection against oxalate and calcium oxalate crystal induced oxidative damage to renal epithelium. J Urol 2005;173:640-646.
25. Tungsanga K, Sriboonlue P, Futrakul P, Yachantha C, Tosukhowong P. Renal tubular cell damage and oxidative stress in renal stone patients and the effect of potassium citrate treatment. Urol Res 2005;33:65-69.
26. Tanner GA. Potassium citrate/citric acid intake improves renal function in rats with polycystic kidney disease. J Am Soc Nephrol 1998;9:1242-1248.
27. Gadola L, Noboa O, Márquez MN, Rodriguez MJ, Nin N, et al. Calcium citrate ameliorates the progression of chronic renal injury. Kidney Int 2004;65:1224-1230.
28. Hess B. Acid-base metabolism: implications for kidney stones formation. Urol Res 2006;34:134-138.
29. Hirayama A, Uehara S, Honjo K, Izumiyama S, Itagaki Y. Clinical effect of Uralyt-U for hyperuricemia associated with hypertension. Jpn J Med Pharm Sci 1991;25: 201-206.
30. Phisitkul S, Khanna A, Simoni J, Broglio K, Sheather S, et al. Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR. Kidney Int 2010;77:617-623.
31. Rosenfeld JB. Effect of long-term allopurinol administration on serial GFR in normotensive and hypertensive subjects. Adv Exp Med Biol 1974;41:581-596.
32. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007;39:1227-1233.
33. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006;47:51-59.
34. Elion GB, Kovensky A, Hitchings GH. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharmacol 1966;15:863-880.
35. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.
36. Lee HY, Ariyasinghe JT, Thirumoorthy T. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction? Singapore Med J 2008; 49:384-387.
37. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003;41:1183-1190.
38. Maalouf NM, Cameron MA, Moe OW, Adams-Huet B, Sakhaee K. Low urine pH: a novel feature of the metabolic syndrome. Clin J Am Soc Nephrol 2007;2:883-888.
39. Abate N, Chandalia M, Cabo-Chan AV Jr, Moe OW, Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 2004;65:386-392.
40. Takahashi S, Inokuchi T, Kobayashi T, Ka T, Tsutsumi Z, et al. Relationship between insulin resistance and low urinary pH in patients with gout, and effects of PPARalpha agonists on urine pH. Horm Metab Res 2007;39:511-514.
41. Hara S, Tsuji H, Ubara Y, Miyakawa M, Amakawa K, et al. Significance of hyperuricemia and low urine pH as a risk factor for CKD in general health check population on cohort study during five years. American Society of Nephrology 2007;SA-PO907.